Managers’ transactions
June 24, 2024
Announcement no. 16
Managers’ transactions
In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 15, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them.
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Gry Louise Husby Larsen |
| 2. Reason for the notification | |
| a) Position/status | Chief Legal Officer and Executive Vice President of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0063068374 to be merged with permanent ISIN code DK0011048619, expected no later than on 1 July 2024 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with private placement) |
| c) Price(s) and volume(s) | Price: DKK 1.628, Volume: 122,850 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2024-06-24 5:00 a.m. UTC (7:00 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Peter Mørch Eriksen |
| 2. Reason for the notification | |
| a) Position/status | Chief Executive Officer of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0063068374 to be merged with permanent ISIN code DK0011048619, expected no later than on 1 July 2024 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with private placement) |
| c) Price(s) and volume(s) | Price: DKK 1.628, Volume: 614,250 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2024-06-24 5:00 a.m. UTC (7:00 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Mats Thorén |
| 2. Reason for the notification | |
| a) Position/status | Member of the Board of Directors of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0063068374 to be merged with permanent ISIN code DK0011048619, expected no later than on 1 July 2024 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with private placement) |
| c) Price(s) and volume(s) | Price: DKK 1.628, Volume: 214,987 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2024-06-24 5:00 a.m. UTC (7:00 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
For further information, please contact:
Tim Eriksen, +45 4529 0000, [email protected]
Claus Thestrup, HC Andersen Capital, 45 4529 0000, [email protected]
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577, [email protected]
About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/.
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.
Attachment
